GLRA3 and Cognitive impairment: An innovative therapeutic drug candidate for cognitive impairment in AD is the agonist of α7-Nicotinic acetylcholine receptor (α7-nAChR), which is a ligand-gated ion channel responsible for acetylcholine (ACh) binding.